Neuroinflammation After Myocardial Infarction - Imaging Substudy

Last updated: November 1, 2024
Sponsor: University of Alabama at Birmingham
Overall Status: Active - Not Recruiting

Phase

1

Condition

Hypercholesterolemia

Myocardial Ischemia

Congestive Heart Failure

Treatment

[18F]DPA-714-PET/MRI

Clinical Study ID

NCT03968445
IRB-300003221 R19-045
  • Ages > 21
  • All Genders

Study Summary

The purpose of the study is to see if positron emission tomography and magnetic resonance imaging (PET/MRI) with an investigational drug called [18F]DPA-714 will show inflammation in the brain after a heart attack. This study may help physicians and researchers better understand the role of brain inflammation in heart disease and develop new treatments to protect the brain.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Participation in UAB IRB protocol "Neuroinflammation After Acute MyocardialInfarction" (IRB-300002751, PI Lazar).

  2. 21 years of age or older

  3. . English speaking with at least 8th grade education

  4. High or mixed affinity binder for TSPO ligands based on genotyping for singlenucleotide polymorphism (SNP) rs6971.

  5. Admission to UAB Hospital for ST-elevation acute myocardial infarction (AMI) andtreatment with percutaneous coronary intervention (PCI) OR Undergoing electivepercutaneous coronary intervention (PCI)

Exclusion

Exclusion Criteria:

  1. Contraindication to MRI

  2. Pregnancy

  3. Lactation

  4. Serious medical co-morbidity that may interfere with participation

  5. Prior myocardial infarction

  6. Severe anemia

  7. Prior coronary artery bypass grafting

  8. Prior angioplasty and/or coronary artery stent placement (PCI group only)

  9. History of traumatic head injury defined by a loss of consciousness ≥30 minutes orseizure at the time of injury

  10. Diagnosis of major depression

  11. Diagnosis of dementia

  12. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.

Study Design

Total Participants: 6
Treatment Group(s): 1
Primary Treatment: [18F]DPA-714-PET/MRI
Phase: 1
Study Start date:
October 17, 2019
Estimated Completion Date:
October 31, 2028

Study Description

The primary objective of this study is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand [18F]DPA-714 in individuals with recent AMI. The basic premise is that AMI leads to systemic inflammation that includes inflammation in the brain. The PET tracer [18F]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation. The estimates of brain TSPO binding in patients with recent AMI will be compared to a matched group of patients who have undergone a recent elective PCI procedure.

Connect with a study center

  • University of Alabama at Birmingham Medical Center

    Birmingham, Alabama 35294
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.